vendredi 5 août 2022

BILLET DU 5 AOÛT 2022. NOUVELLES SUR LES EFFETS NOCIFS DU VACCIN

FB n'ayant toujours pas débloqué mon compte, je vais utiliser désormais mon Blog que j'avais abandonné, bien à tort.

 Décès anormaux en Nouvelle Zélande :

https://www.francesoir.fr/societe-sante/vaccin-contre-la-covid-19-des-medecins-neozelandais-sonnent-alerte 


Antibody-dependent enhancement :


2020 Aug;584(7821):353-363.
 doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13.

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Affiliations 

Abstract

Antibody-dependent enhancement (ADE) of disease is a general concern for the development of vaccines and antibody therapies because the mechanisms that underlie antibody protection against any virus have a theoretical potential to amplify the infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in the pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we review observations relevant to the risks of ADE of disease, and their potential implications for SARS-CoV-2 infection. At present, there are no known clinical findings, immunological assays or biomarkers that can differentiate any severe viral infection from immune-enhanced disease, whether by measuring antibodies, T cells or intrinsic host responses. In vitro systems and animal models do not predict the risk of ADE of disease, in part because protective and potentially detrimental antibody-mediated mechanisms are the same and designing animal models depends on understanding how antiviral host responses may become harmful in humans. The implications of our lack of knowledge are twofold. First, comprehensive studies are urgently needed to define clinical correlates of protective immunity against SARS-CoV-2. Second, because ADE of disease cannot be reliably predicted after either vaccination or treatment with antibodies-regardless of what virus is the causative agent-it will be essential to depend on careful analysis of safety in humans as immune interventions for COVID-19 move forward.


Review
 
2020 Oct;5(10):1185-1191.
 doi: 10.1038/s41564-020-00789-5. Epub 2020 Sep 9.

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Affiliations 

Abstract

Antibody-based drugs and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and clinical development. Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials. Here, we describe key ADE mechanisms and discuss mitigation strategies for SARS-CoV-2 vaccines and therapies in development. We also outline recently published data to evaluate the risks and opportunities for antibody-based protection against SARS-CoV-2.


De l'avis des plus grands infectiologues du monde, IOANNIDIS est un génie et sans doute le plus grand d'entre eux.

John Ioannidis: "The argument that vaccines can abort epidemic waves was a centerpiece of the push for aggressive mandates... that would have been previously unimaginable. This resulted in a...blow against public health and its credibility..." 1/2

Aucun commentaire: